Jeffrey M. Besterman

7.0k total citations
98 papers, 5.5k citations indexed

About

Jeffrey M. Besterman is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Jeffrey M. Besterman has authored 98 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 73 papers in Molecular Biology, 25 papers in Oncology and 17 papers in Cancer Research. Recurrent topics in Jeffrey M. Besterman's work include Histone Deacetylase Inhibitors Research (28 papers), Protein Degradation and Inhibitors (21 papers) and Cancer therapeutics and mechanisms (15 papers). Jeffrey M. Besterman is often cited by papers focused on Histone Deacetylase Inhibitors Research (28 papers), Protein Degradation and Inhibitors (21 papers) and Cancer therapeutics and mechanisms (15 papers). Jeffrey M. Besterman collaborates with scholars based in United States, Canada and Zimbabwe. Jeffrey M. Besterman's co-authors include Pedro Cuatrecasas, R B Low, Vincent Duronio, Zuomei Li, Xiuping Fu, Richard M. Hoffman, Intisar Husain, Anna Z. Monosov, Marielle Fournel and A. Robert MacLeod and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Nucleic Acids Research.

In The Last Decade

Jeffrey M. Besterman

98 papers receiving 5.3k citations

Peers

Countries citing papers authored by Jeffrey M. Besterman

Since Specialization

Citations

This map shows the geographic impact of Jeffrey M. Besterman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey M. Besterman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey M. Besterman more than expected).

Fields of papers citing papers by Jeffrey M. Besterman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey M. Besterman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey M. Besterman. The network helps show where Jeffrey M. Besterman may publish in the future.

Co-authorship network of co-authors of Jeffrey M. Besterman

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey M. Besterman. A scholar is included among the top collaborators of Jeffrey M. Besterman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey M. Besterman. Jeffrey M. Besterman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Discovery of bicyclic pyrazoles as class III histone deacetylase SIRT1 and SIRT2 inhibitors 2015 ·Bioorganic & Medicinal Chemistry Letters ·Éric Therrien, (unknown), Natalie Nguyen, Jubrail Rahil, (unknown), Zuomei Li, Marielle Fournel, (unknown), (unknown), Sylvain Lefèbvre, Jinru Wang, Kyle J. MacBeth, Carla Heise, Aaron Nguyen, Jeffrey M. Besterman, Robert Déziel, Amal Wahhab	23
2	Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial 2011 ·The Lancet Oncology ·Anas Younes, Yasuhiro Oki, R. Gregory Bociek, John Kuruvilla, Michelle A. Fanale, Sattva S. Neelapu, Amanda Copeland, Daniela Buglio, Ahmed Galal, Jeffrey M. Besterman, Zuomei Li, Michel Drouin, (unknown), (unknown), Jessica K. Paulus, Yuan Ji, L. Jeffrey Medeiros, Robert E. Martell	156
3	1,2-Diamines as inhibitors of co-activator associated arginine methyltransferase 1 (CARM1) 2009 ·Bioorganic & Medicinal Chemistry Letters ·Éric Therrien, (unknown), Sukhdev Manku, Martin Allan, Natalie Nguyen, (unknown), Marie‐France Robert, Anne-Christine Goulet, Jeffrey M. Besterman, Hannah Nguyen, Amal Wahhab	36
4	N3-Arylmalonamides: A new series of thieno[3,2-b]pyridine based inhibitors of c-Met and VEGFR2 tyrosine kinases 2009 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Stephen Claridge, (unknown), Franck Raeppel, (unknown), Stéphane Raeppel, Michael R. Mannion, Frédéric Gaudette, Nancy Zhou, (unknown), Naomy Bernstein, Robert Déziel, Hannah Nguyen, Normand Beaulieu, Carole Beaulieu, Isabelle Dupont, Jinru Wang, A. Robert MacLeod, Jeffrey M. Besterman, Arkadii Vaisburg	24
5	Induction of an anti-angiogenesis factor, Thrombospondin 1 (TSP-1), by a novel histone deacetylase inhibitor, MGCD0103, in human cancer cells in vitro and in vivo 2008 ·Cancer Research ·Jianhong Liu, Claire Bonfils, Marja Dubay, Hannah Nguyen, Guillermo Garcia‐Manero, Allen S. Yang, (unknown), Robert E. Martell, Jeffrey M. Besterman, Zuomei Li	1
6	In Vivo Properties of MGCD290, an Antifungal Histone Deactylase (HDAC) Inhibitor 2008 ·46th Annual Meeting ·Jeffrey M. Besterman	1
7	Evaluation of the Pharmacodynamic Effects of MGCD0103 from Preclinical Models to Human Using a Novel HDAC Enzyme Assay 2008 ·Clinical Cancer Research ·Claire Bonfils, Ann Kalita, Marja Dubay, Lillian L. Siu, Michael A. Carducci, Gregory K. Reid, Robert E. Martell, Jeffrey M. Besterman, Zuomei Li	81
8	Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors 2008 ·Bioorganic & Medicinal Chemistry Letters ·David Smil, Sukhdev Manku, (unknown), Silvana Leit, Amal Wahhab, (unknown), Marielle Fournel, Christiane R. Maroun, Zuomei Li, (unknown), Alina Nicolescu, Jubrail Rahil, Sylvain Lefèbvre, (unknown), Jeffrey M. Besterman, Robert Déziel	73
9	Sulfamides as novel histone deacetylase inhibitors 2008 ·Bioorganic & Medicinal Chemistry Letters ·Amal Wahhab, David Smil, Alain Ajamian, Martin Allan, (unknown), Éric Therrien, Natalie Nguyen, Sukhdev Manku, Silvana Leit, Jubrail Rahil, (unknown), Aihua Lu, Alina Nicolescu, Sylvain Lefèbvre, (unknown), Marielle Fournel, (unknown), Zuomei Li, Jeffrey M. Besterman, Robert Déziel	26
10	Pharmacological inhibition of histone deacetylases for the treatment of cancer, neurodegenerative disorders and inflammatory diseases 2008 ·Expert Opinion on Drug Discovery ·Claire Bonfils, Donald R. Walkinshaw, Jeffrey M. Besterman, Xiang-Jiao Yang, Zuomei Li	7
11	Phase I and Pharmacologic Study of the Human DNA Methyltransferase Antisense Oligodeoxynucleotide MG98 given as a 21-day Continuous Infusion Every 4 Weeks 2003 ·Investigational New Drugs ·Alison Davis, Karen A. Gelmon, Lillian L. Siu, Malcolm J. Moore, Carolyn D. Britten, Nisha Mistry, Henry J. Klamut, Susan D’Aloisio, Martha MacLean, Nancy Wainman, (unknown), P. Firby, Jeffrey M. Besterman, Gregory K. Reid, Elizabeth A. Eisenhauer	78
12	(2-Amino-phenyl)-amides of ω-substituted alkanoic acids as new histone deacetylase inhibitors 2003 ·Bioorganic & Medicinal Chemistry Letters ·Arkadii Vaisburg, Naomy Bernstein, Sylvie Fréchette, Martin Allan, (unknown), Silvana Leit, Oscar Moradei, Giliane Bouchain, Jinru Wang, Soon Hyung Woo, Marielle Fournel, Pu Yan, Marie-Claude Trachy-Bourget, Ann Kalita, Carole Beaulieu, Zuomei Li, A. Robert MacLeod, Jeffrey M. Besterman, Daniel Delorme	21
13	Design and synthesis of a novel class of histone deacetylase inhibitors 2001 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Giliane Bouchain, Sylvie Fréchette, Soon Hyung Woo, (unknown), Silvana Leit, Marielle Fournel, Pu Yan, Marie-Claude Trachy-Bourget, Carole Beaulieu, Zuomei Li, Jeffrey M. Besterman, Daniel Delorme	52
14	Down-regulation of Human DNA-(Cytosine-5) Methyltransferase Induces Cell Cycle Regulators p16 and p21WAF/Cip1 by Distinct Mechanisms 1999 ·Journal of Biological Chemistry ·Marielle Fournel, Przemysław Sapieha, Normand Beaulieu, Jeffrey M. Besterman, A. Robert MacLeod	93
15	Topoisomerase I Inhibition by the Camptothecin Analog G1147211C 1996 ·Annals of the New York Academy of Sciences ·Jeffrey M. Besterman	14
16	Rigid Analogs of Camptothecin as DNA Topoisomerase I Inhibitors 1995 ·Journal of Medicinal Chemistry ·Karen Lackey, Jeffrey M. Besterman, (unknown), Peter Leitner, (unknown), Daniel D. Sternbach	26
17	Coordinated activation of corneal wound response genes in vivo as observed by in situ hybridization 1995 ·Experimental Eye Research ·Lisa Ross, (unknown), Alan D. Proia, Marc R. Sontag, D. M. Brown, Antonio Laurenza, Jeffrey M. Besterman	7
18	Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs 1993 ·Journal of Medicinal Chemistry ·Monroe E. Wall, Mansukh C. Wani, Allan W. Nicholas, Govindarajan Manikumar, (unknown), Linda B. Moore, Anne T. Truesdale, (unknown), Jeffrey M. Besterman	120
19	Association and metabolism of exogenously-derived lysophosphatidylcholine by cultured mammalian cells: kinetics and mechanisms 1992 ·Biochemistry ·Jeffrey M. Besterman, Paul L. Domanico	25
20	DNA Triple-Helix Formation at Physiologic pH and Temperature 1991 ·PubMed ·Jeffery C. Hanvey, E.M. Williams, Jeffrey M. Besterman	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact